Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CLPP | Q16740 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6409158 | 0.99 | POLB (0.45) | POLBHCRTR2CXCR4SIGMAR1ROCK2 | |
| SCHEMBL6409327 | 0.92 | HCRTR2 (0.43) | HCRTR2SIGMAR1ROCK2ROCK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6409905 | 0.91 | HCRTR2 (0.43) | HCRTR2SIGMAR1ROCK2ROCK1ALDH1A1 | |
| SCHEMBL6415267 | 0.90 | HTT (0.43) | HCRTR2SIGMAR1CCR5 | |
| Hydrochloric Acid SCHEMBL6408556 | 0.89 | HTT (0.42) | HCRTR2SIGMAR1CCR5 | |
| SCHEMBL6412985 | 0.89 | HCRTR2 (0.40) | HCRTR2SIGMAR1ROCK2ROCK1ALDH1A1 | |
| SCHEMBL6411451 | 0.89 | MAPK1 (0.44) | POLBHCRTR2SIGMAR1ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL6415597 | 0.89 | HCRTR2 (0.40) | HCRTR2SIGMAR1ROCK2ROCK1ALDH1A1 | |
| SCHEMBL6409526 | 0.88 | GAA (0.43) | POLBHCRTR2ROCK2ROCK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6412418 | 0.88 | MAPK1 (0.43) | POLBHCRTR2SIGMAR1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | POLB 3564/4885HCRTR2 247/4885CXCR4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.